Clinical Trials
New discoveries in Tang lab have been actively translated to the clinic to improve the treatment for cancer patients. Currently, there are five on-going IIT clinical trials of CAR-T cell therapy developed by Tang lab. So far, the clinical results have been reported as an oral presentation in Late-Breaking Research Minisymposium at AACR 2024, an oral presentation in Late-Breaking Abstracts II at ASGCT 2024, an oral presentation at EHA 2024, and a poster at the Society of Hematologic Oncology (SOHO) 2024.
Disease | Status | Clinical Trial Registration |
r/r B-ALL | Recruiting | NCT05747157 |
r/r DLBCL | Recruiting | NCT05715606 |
r/r DLBCL | Recruiting | NCT06120166 |
r/r CD19-positive B cell Hematological Malignancies | Recruiting | NCT06277011 |
r/r CD19-positive B cell Hematological Malignancies (6 Months to 18 Years) | Recruiting | NCT06393335 |
Disclosure: Prof. Li TANG is an inventor of related patents. He is a co-founder, shareholder and advisor of Leman Biotech, a spin-off start-up biotech company from EPFL. The interests of L.T. were reviewed and managed by EPFL.
Any inquiries regarding the on-going clinical trials should be addressed to [email protected].